ClinicalTrials.gg
CompletedNCT02749799Updated Mar 7, 2024Results posted

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

A Phase 4 interventional study of DFD-01 (betamethasone dipropionate) Spray, 0.05% in Plaque Psoriasis, sponsored by Primus Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Primus Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing betamethasone dipropionate in Psoriasis — 1 open to participants now, 1 under way, 1 of them phase 3. betamethasone dipropionate · Psoriasis.

Enrollment
21st of 29
45 · median 224
Started
2016
with 2 others
Phase 4
7 of 29
none open now
Registered
17th of 29
by date
Lead sponsor
1 of 29
Primus Pharmaceuticals

Among the 29 studies testing betamethasone dipropionate in Psoriasis, this one is the 21st largest by enrollment, is one of 3 that started in 2016, is one of 7 in phase 4, and was the 17th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 29 studies testing betamethasone dipropionate in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About betamethasone dipropionate

betamethasone dipropionate: first FDA approval 1975 (DIPROSONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing betamethasone dipropionate in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.

Read the detailed description

This multicenter, multi-dose, open-label study was designed to assess clinical response and patient-reported satisfaction after dosing with DFD-01 twice daily for 28 days. The product was approved for the treatment of mild to moderate plaque psoriasis by the FDA on February 5, 2016 before the first patient was enrolled.

Forty five (45) adult males and females, 18 years of age and older with a clinical diagnosis of moderate plaque psoriasis who met inclusion/exclusion criteria were randomized at the Baseline Visit. Each site attempted to enroll 50% of the patients with 3% to 10% body surface area (BSA) involved and 50% of the patients with > 10% BSA involved.

The initial dose of study product was self-administered by the patient and supervised by clinic staff during the Baseline Visit. Patients continued to apply the study product to all affected areas (avoiding the face, scalp, groin, axillae or other intertriginous areas) twice daily (approximately 12 hours apart) for 28 days. Patients visited the clinic for a total of up to five scheduled visits:

  • Screening (Day -60 to 1)*
  • Baseline (Day 1)
  • Interim Visit (Day 8 ± 2)
  • Interim Visit (Day 14 ± 3)
  • End of Study (Day 29 ± 3)
03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient understands the study procedures and agrees to participate by giving written . Patients must be willing to authorize use and disclosure of protected health information collected for the study.
  2. Patient must be at least 18 years of age.
  3. Patient must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis.
  4. At least 3% Body Surface Area involved, not including the face, scalp, groin, axillae and other intertriginous areas.
  5. Female patients of must agree to use during the study which can include abstinence with an adequate secondary option should the patient become sexually active. A female is considered of childbearing potential unless she is:

    1. for at least 12 months prior to study product administration;
    2. Without a uterus and/or both ovaries; or has been surgically sterile (i.e., tubal ligation) for at least 6 months prior to study product administration.

    Reliable methods of contraception are:

    1. Hormonal methods or intrauterine device in use > 90 days prior to study product administration; or
    2. Barrier methods plus spermicide in use at least 14 days prior to study product administration.
    3. Partner has had a vasectomy at least 3 months previous to study product administration.
    4. Essure® that has been in place for at least 3 months before the screening visit with radiograph confirmation of fallopian tube blockage.

    Exception: Sexually inactive female patients of childbearing potential are not required to practice a reliable method of contraception and may be enrolled at the Investigator's discretion provided that they are counseled to remain sexually inactive for the duration of the study and understand the possible risks involved in getting pregnant during the study. An abstinent female must agree that if she becomes sexually active during the study she will use an acceptable form of contraception.

    All women must complete a urine pregnancy test at the Baseline Visit (Day 1) and the test result must be negative to be eligible for enrollment.

  6. Patient must be in good general health as determined by the investigator and supported by the medical history and normal or not abnormal vital signs (temperature, blood pressure and pulse).
  7. Patient is physically able to apply study product to all affected areas or can obtain help.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
  2. Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis).
  3. Presence of pigmentation, extensive scarring, pigmented lesions, tattoos or sunburn that could interfere with the rating of efficacy parameters.
  4. History of psoriasis unresponsive to topical treatments.
  5. History of organ transplant requiring , , or other immunocompromised state.
  6. Ongoing infection (including viral lesions of the skin, fungal or bacterial skin infections, ulcers or wounds) or evidence of chronic infectious disease, history of or current system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation in the study.
  7. Use within 180 days before Baseline Visit of biologic treatment for psoriasis (e.g., infliximab, adalimumab, etanercept, ustekinumab, secukinumab, or alefacept).
  8. Have received treatment for any type of cancer within 5 years of the Baseline Visit, except skin cancer and cervical cancer (in situ) that are allowed if at least 1 year before the Baseline Visit.
  9. Use within 60 days before the Baseline Visit of: 1) systemic or topical immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea) or 3) oral retinoids (e.g., acitretin, isotretinoin).
  10. Use within 30 days before the Baseline Visit of: 1) systemic , 2) Ultraviolet light therapy, or 3) systemic anti-inflammatory agents* (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine). * Over-the-counter strength non-steroidal anti-inflammatory drugs used for transitional and common aches are permitted during the study.
  11. Use within 14 days before the Baseline Visit of: 1) topical antipsoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene), 2) topical retinoids (e.g., tazarotene, tretinoin) or 3) topical corticosteroids.
  12. History of unresolved or current hypothalamic-pituitary-adrenal suppression or significant endocrine disorder (Cushing's disease or Addison's disease) or uncontrolled diabetes.
  13. Patients who have participated in a study of an drug 30 days before the Baseline Visit.
  14. Patients unable to comply with study requirements.
  15. Female patients who are pregnant (or planning to become pregnant) or breast-feeding.
  16. History of drug or alcohol abuse within the last year.
  17. Planned use of a tanning bed during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    DFD-01 (betamethasone dipropionate) Spray, 0.05%

    DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.

    Drug: DFD-01 (betamethasone dipropionate) Spray, 0.05%

Interventions

  • DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.

    Also known as: Sernivo (betamethasone dipropionate, 0.05%) Spray

06

What researchers measure

Primary outcomes

  1. Change in Investigator's Global Assessment Grade

    The mean change in the IGA score from baseline to Day 14 was assessed. IGA score is a static assessment of disease severity and is based on overall severity of signs at each visit. It's a 4-point scale where '0' is absent disease and '4' is 'Severe/Very Severe' disease. A lower score at the end of the study compared to baseline (negative change), indicates an improvement in the disease condition.

    Time frame: Change from Baseline to Day 14.

  2. Change in Percent Body Surface Area (BSA) Involved.

    Change in the BSA of involvement with psoriasis from baseline to Day 14 was assessed. BSA was assessed at Baseline, Days 8, 14 and 29.

    Time frame: Change from Baseline to Day 14.

  3. Change in Dermatology Life Quality Index (DLQI)

    DLQI is a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (i.e., negative change score) indicates improvement in the Quality of Life.

    Time frame: Change from Baseline to Day 14.

07

Results

Posted Oct 5, 2020

Participant flow

Participant flow — Overall Study
MilestoneDFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Started45
Completed37
Not completed8
Withdrew: Adverse event2
Withdrew: Lost to follow-up4
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange in Investigator's Global Assessment Grade

The mean change in the IGA score from baseline to Day 14 was assessed. IGA score is a static assessment of disease severity and is based on overall severity of signs at each visit. It's a 4-point scale where '0' is absent disease and '4' is 'Severe/Very Severe' disease. A lower score at the end of the study compared to baseline (negative change), indicates an improvement in the disease condition.

Time frame:
Change from Baseline to Day 14.
Reported as:
Mean · units on a scale
Change in Investigator's Global Assessment Grade
units on a scaleDFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Change in Investigator's Global Assessment Grade-0.8 ± 0.77
PrimaryChange in Percent Body Surface Area (BSA) Involved.

Change in the BSA of involvement with psoriasis from baseline to Day 14 was assessed. BSA was assessed at Baseline, Days 8, 14 and 29.

Time frame:
Change from Baseline to Day 14.
Reported as:
Mean · percentage of BSA
Change in Percent Body Surface Area (BSA) Involved.
percentage of BSADFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Change in Percent Body Surface Area (BSA) Involved.-1.3 ± 2.82
PrimaryChange in Dermatology Life Quality Index (DLQI)

DLQI is a simple, compact, and practical questionnaire to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. The participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A lower score (i.e., negative change score) indicates improvement in the Quality of Life.

Time frame:
Change from Baseline to Day 14.
Reported as:
Mean · units on a scale
Change in Dermatology Life Quality Index (DLQI)
units on a scaleDFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Change in Dermatology Life Quality Index (DLQI)-6.6 ± 6.72

Adverse events

Collected over Adverse events were recorded from the time of informed consent up to the end of treatment (an average of 29 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DFD-01 (Betamethasone Dipropionate) Spray, 0.05%1/45 (2.2%)1/45 (2.2%)0/45 (0%)
Most frequent serious events
Most frequent serious events
EventDFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Hip Fracture due to accidental fallInjury, poisoning and procedural complications1/45
Acute Kidney InjuryRenal and urinary disorders1/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Mean50.7 ± 16.8
Sex: Female, Male
Sex: Female, Male(Participants)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Female21
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Hispanic or Latino0
Not Hispanic or Latino45
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander2
Black or African American6
White37
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
United States45
Percent Body Surface Area Involved
Percent Body Surface Area Involved(Percentage of Body Surface Area)DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Mean11.9 ± 10.0
08

Study locations

4 sites
  • Site Four
    Arlington Heights, Illinois 60005, United States
  • Site Two
    New Albany, Indiana 47150, United States
  • Site One
    Louisville, Kentucky 40202, United States
  • Site Three
    Las Vegas, Nevada 89129, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jul 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2020, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2016
First posted
Apr 25, 2016
Start
Feb 2016
Primary completionActual
Jul 2016
CompletionActual
Aug 2016
Results first posted
Oct 5, 2020
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02749799
Lead sponsor
Primus Pharmaceuticals
Collaborators
Prosoft Clinical
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Feb 2016
Primary completion
Jul 2016
Completion
Aug 2016
Results posted
Oct 5, 2020
Last update
Mar 7, 2024

Study contacts

Srinivas Sidgiddi, MD
study director · Dr. Reddy's Laboratories Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Betamethasone dipropionate

Start the discussion